@article{e8f7c432755443209581c95a817df6c7,
title = "A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach",
abstract = "The global fight against Alzheimer's disease (AD) poses unique challenges for the field of neuropsychology. Along with the increased focus on early detection of AD pathophysiology, characterizing the earliest clinical stage of the disease has become a priority. We believe this is an important time for neuropsychology to consider how our approach to the characterization of cognitive impairment can be improved to detect subtle cognitive changes during early-stage AD. The present article aims to provide a critical examination of how we define and measure cognitive status in the context of aging and AD. First, we discuss pitfalls of current methods for defining cognitive impairment within the context of research shifting to earlier (pre)symptomatic disease stages. Next, we introduce a shift towards a more continuous approach for identifying early markers of cognitive decline and characterizing progression and discuss how this may be facilitated by novel assessment approaches. Finally, we summarize potential implications and challenges of characterizing cognitive status using a continuous approach.",
keywords = "Cognitive assessment, early diagnosis, neuropsychology, preclinical Alzheimer's disease, progression",
author = "Jutten, {Roos J.} and Louisa Thompson and Sikkes, {Sietske A. M.} and Paul Maruff and Molinuevo, {Jos{\'e} Luis} and Henrik Zetterberg and Jessica Alber and David Faust and Serge Gauthier and Michael Gold and John Harrison and Lee, {Athene K. W.} and Snyder, {Peter J.}",
note = "Funding Information: HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and the UK Dementia Research Institute at UCL. AL and JA are partially supported by Institutional Development Award Number U54GM115677 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds Advance Clinical and Translational Research (Advance-CTR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2022 - IOS Press. All rights reserved.",
year = "2022",
doi = "10.3233/JAD-215098",
language = "English",
volume = "86",
pages = "511--524",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",
}